Back to first-pass browser

First-pass extracted concept

blood and urine biomarkers for renal fibrosis

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This category covers blood- and urine-based markers proposed for noninvasive assessment of renal fibrosis. The abstract groups ECM metabolism markers, inflammatory factors, tubular injury markers, and extracellular vesicles under this approach.

Source 1DOIPubMed

What problem it solves

It addresses the need for less invasive fibrosis assessment than percutaneous renal biopsy and may support dynamic monitoring.

Source 1DOIPubMed

What it does not solve

The abstract does not establish a single biomarker as replacing biopsy, and it notes bottlenecks in clinical translation.

Source 1DOIPubMed

Evidence Snippets

These include: (1) blood and urine biomarkers such as markers of ECM metabolism, inflammatory factors, tubular injury markers, and extracellular vesicles;
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1modality scopesupports2025Source 1DOIPubMed

Noninvasive diagnostic techniques for renal fibrosis include blood and urine biomarkers and advanced imaging modalities.

Quoted textsource-backed
In recent years, significant advances have been made in noninvasive diagnostic techniques. These include: (1) blood and urine biomarkers ...; (2) imaging modalities including novel ultrasound techniques, shear wave elastography, functional magnetic resonance imaging (MRI) methods such as diffusion-weighted imaging, blood oxygen level-dependent MRI, magnetic resonance elastography, and positron emission tomography/computed tomography using radiotracers targeting fibrosis-associated molecules such as 68Ga-FAPI.
Claim 2objectivesupports2025Source 1DOIPubMed

The aim is to develop a multimodal, noninvasive assessment system for earlier fibrosis detection, stratified disease management, and precise intervention targeting fibrogenic pathways.

Quoted textsource-backed
The aim is to develop a multimodal, noninvasive assessment system to enable earlier fibrosis detection, stratified disease management, and precise intervention targeting fibrogenic pathways, ultimately improving renal disease outcomes.
Claim 3review scopesupports2025Source 1DOIPubMed

The review emphasizes diagnostic performance, utility for dynamic monitoring, and bottlenecks in clinical translation of noninvasive renal fibrosis diagnostics.

Quoted textsource-backed
This review systematically summarizes the latest evidence on the above biomarkers and advanced imaging modalities, with an emphasis on their diagnostic performance (sensitivity/specificity), utility for dynamic monitoring, and bottlenecks in clinical translation.